Butalbital
drugOn this page
Also known as AlisobumalAllylbarbituric acidButalbital ciiiButalbital component of anoquanButalbital component of axotalButalbital component of bancapButalbital component of bucetButalbital component of butapapButalbital component of esgicButalbital component of femcetButalbital component of fioricetButalbital component of fiorinalButalbital component of lanorinalButalbital component of phrenilinButalbital component of sedapapButalbital component of tenconButalbital component of triadButalbital component of triaprinItobarbital
Summary
Butalbital (CHEMBL454) is an approved small-molecule analgesic; indicated across 1 condition including migraine disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 1 condition
- Chemistry: 224.26 Da · C11H16N2O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL454 |
| Name | Butalbital |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 2481 |
| ChEBI | CHEBI:102524 |
| Molecular formula | C11H16N2O3 |
| Molecular weight | 224.26 |
| InChIKey | UZVHFVZFNXBMQJ-UHFFFAOYSA-N |
SMILES: CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C
IUPAC name: 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
ChEBI definition: A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. Frequently combined with other medicines, such as aspirin, paracetamol and codeine, it is used for treatment of pain and headache.
Pharmacological roles (ChEBI): sedative, analgesic.
Also known as: Alisobumal, Allylbarbituric acid, Butalbital, Butalbital ciii, Butalbital component of anoquan, Butalbital component of axotal, Butalbital component of bancap, Butalbital component of bucet, Butalbital component of butapap, Butalbital component of esgic, Butalbital component of femcet, Butalbital component of fioricet
Patent coverage: 4,864 distinct patent families (11,023 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 10,859 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| migraine disorder | 4 | MONDO:0005277 | MONDO:0005277 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: migraine disorder